For spine fusion, two formulations are in clinical testing:

OSTEOGROW-A: OSTEOGROW supplemented with allograft from a bone bank currently tested in an ongoing multicentre double-blinded randomized Phase II clinical trial in patients undergoing posterolateral lumbar interbody fusion (PLIF; n=143, PhII, follow-up 20 months - April 2023).

OSTEOGROW-B: OSTEOGROW enriched with host bone from the patient's spine tested in a multicentre double-blinded randomized Phase II clinical trial in patients undergoing transforaminal lumbar interbody fusion (TLIF; n=60, PhI/II, completed). Promising safety and efficacy data were obtained: no therapy-related serious side effects and inflammation without soft tissue ossification. Patients treated with OSTEOGROW-B had accelerated and enhanced vertebral bodies fusion.

Read more:

• Evaluation of synthetic ceramics as compression resistant matrix to promote osteogenesis of autologous blood coagulum containing recombinant human bone morphogenetic protein 6 in rabbit posterolateral lumbar fusion model
  DOI: 10.1016/j.bone.2020.115544
• Autologous blood coagulum is a physiological carrier for BMP6 to induce new bone formation and promote posterolateral lumbar spine fusion in rabbits
  DOI: 10.1002/term.2981